An Open-Label Study to Evaluate the Prevalence of Phenotypic Poor Metabolizers at CYP2D6 Among Venlafaxine-Treated Outpatients With Depression.

Trial Profile

An Open-Label Study to Evaluate the Prevalence of Phenotypic Poor Metabolizers at CYP2D6 Among Venlafaxine-Treated Outpatients With Depression.

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Jan 2011

At a glance

  • Drugs Venlafaxine (Primary)
  • Indications Depressive disorders
  • Focus Pharmacogenomic; Pharmacokinetics
  • Sponsors Wyeth
  • Most Recent Events

    • 21 May 2010 Actual patient number changed from 966 to 971 added as reported by ClinicalTrials.gov.
    • 07 Aug 2009 Actual number of patients (966) added as reported by ClinicalTrials.gov.
    • 07 Aug 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top